BrittBA. Malignant hyperthermia. Can Anaesth Soc J1985;32(6):666–667.
2.
BrittBA, KalowW.Malignant hyperthermia: A statistical review. Can Anaesth Soc J1970;17:293–315.
3.
TomarkenJL, BrittBA. Malignant hyperthermia. Ann Emerg Med1987;16(11):1253–1265.
4.
WilhoitRD, BrownREJr, BaumanLA. Possible malignant hyperthermia in a 7 week old infant. Anesth Analg1989;68(5):688–691.
5.
KripkeBJ, BlanckTJJ, SizemoreDA, ComunaleFL, GruenerR.Association of post-anaesthetic hyperthermia with abnormal muscle characteristics: A case report. Can Anaesth Soc J1983;30(3):290–294.
6.
LarachMG, RosenbergH, LarachDR, BroennleAH. Prediction of malignant hyperthermia susceptibility by clinical signs. Anesthesiology1987;66(4):547–550.
7.
JensenAG, BachV, WernerMU, NeilsenHK, JensenMH. A fatal case of malignant hyperthermia following isoflurane anaesthesia. Acta Anaesthesiol Scand1986;30:293–294.
8.
JohannessonG, VeelT, RogstadiusJ.Malignant hyperthermia during isoflurane anaesthesia: A case report. Acta Anaesthesiol Scand1987;31(3):231–232.
9.
MooreDC. Ester or amide local anesthetics in malignant hyperthermia-Who knows?Anesthesiology1986;64(2):294–296.
10.
PaasukeRT, BrownellAKW. Amide local anesthetics and malignant hyperthermia. Can Anaesth Soc J1986;33(2):126–129.
11.
BrownellAKW, PaasukeRT. Use of local anesthetics in malignant hyperthermia. Can Med Assoc J1986;134:993–994.
HeffronJJA. Malignant hyperthermia: Biochemical aspects of the acute episode. Br J Anaesth1988;60(3):274–278.
17.
BaudendistelL, GoudsouzianN, CoteC, StraffordM.End-tidal CO2 monitoring: Its use in the diagnosis and management of malignant hyperthermia. Anaesthesia1984;39:1000–1003.
18.
TrinerL, ShermanJ.Potential value of expiratory carbon dioxide measurement in patients considered to be susceptible to malignant hyperthermia. Anesthesiology1981;55:482.
19.
AtkinsonRS, RushmanGB, LeeJA. A synopsis of anaesthesia. England: IOP Publishing Limited, 1987.
20.
BaconAK. Pulse oximetry in malignant hyperthermia. Anaesth Intensive Care1989;17(2):208–210.
21.
WlodyGS. Malignant hyperthermia-Potential crisis in patient care. AORN J1989;50(2):286–290.
AdnetPJ, Krivosic-HorberRM, AdamantidisMM, . The association between neuroleptic malignant syndrome and malignant hyperthermia. Acta Anaesthesiol Scand1989;33(8):676–680.
28.
GronertGA, HildeJH, TheyeRA. Dantrolene in porcine malignant hyperthermia. Anesthesiology1976;44(6):488–495.
29.
KerrDD, JonesEW, NelsonTE, GatzEE. Treatment of malignant hyperthermia in swine. Anesth Analg1973;52(5):734–739.
30.
RyanJF. Treatment of acute hyperthermia crises. In: BrittBA, ed. Malignant hyperthermia. Int Anesthesiol Clin1979;17:153–168.
31.
SchmalbruchH.A freeze-fracture study of the plasma membrane of muscle fibers of a patient with chronic creatine kinase elevation suspected for malignant hyperthermia. J Neuropathol Exp Neurol1979;38:407–418.
32.
MathieuA, BogosianAJ, RyanJF, CroneRK, CrockerD.Recrudescence after survival of an initial episode of malignant hyperthermia. Anesthesiology1979;51(5):454–455.
33.
HarrisonGG. Control of malignant hyperpyrexia syndrome in MHS swine by dantrolene sodium. Br J Anaesth1975;47:62–65.
34.
PanditSK, KotharySP, CohenPJ. Orally administered dantrolene for prophylaxis of malignant hyperthermia. Anesthesiology1979;50:156–158.
35.
KolbME, HorneML, MartzRM. Dantrolene in human malignant hyperthermia. Anesthesiology1982;56:254–262.
36.
BrittBA. Dantrolene. Can Anaesth Soc J1984;31(1):61–75.
37.
CuncliffeM, LermanJ, BrittBA. Is prophylactic dantrolene indicated for malignant hyperthermia susceptible patients undergoing elective surgery?Can Anaesth Soc J1986;33(Part 2):S113.
38.
FitzgibbonsDC. Malignant hyperthermia following pre-operative oral administration of dantrolene. Anesthesiology1981;54:73–75.
39.
RuhlandG, HinkleAJ. Malignant hyperthermia after oral and intravenous pretreatment with dantrolene in a patient susceptible to malignant hyperthermia. Anesthesiology1984;60:159–160.
40.
WingardDW. Controversies regarding the prophylactic use of dantrolene for malignant hyperthermia (letter). Anesthesiology1983;58:489–490.
41.
FlewellenEH, NelsonTE. Prophylactic and therapeutic doses of dantrolene for malignant hyperthermia (letter). Anesthesiology1984;61:477.
42.
HarrisonGG. Dantrolene-Dynamics and kinetics. Br J Anaesth1988;60(3):279–286.
43.
WatsonCB, ReiersonN, NorfleetEA. Clinically significant muscle weakness induced by oral dantrolene sodium prophylaxis for malignant hyperthermia. Anesthesiology1986;65:312–314.
44.
DriessenJJ, WuisEW, GielenMJM. Prolonged vecuronium neuromuscular blockade in a patient receiving orally administered dantrolene. Anesthesiology1985;62(4):523–524.
45.
AldreteJA. Advances in the diagnosis and treatment of malignant hyperthermia. Acta Anaesthesiol Scand1981;25:477–483.
46.
DenboroughMA, EbelingP, KingJO, ZapfP.Myopathy and malignant hyperpyrexia. Lancet1970;1:1138–1140.
DenboroughMA, DennettX, AndersonRMD. Central core disease and malignant hyperpyrexia. Br Med J1973;1:272–274.
49.
RyanCA, Al-GhandiAS, GayleM, FinerNN. Osteogenesis imperfecta and hyperthermia. Anesth Analg1989;68(6):811–814.
50.
BrittBA. Preanesthetic diagnosis of malignant hyperthermia. In: BrittBA, ed. Malignant hyperthermia. Int Anesthesiol Clin1979;17:63–96.
51.
OrdingH.Diagnosis of susceptibility to malignant hyperthermia in man. Br J Anaesth1988;60(3):287–302.
52.
MeltonAT, MartucciRW, KienND, GronertGA. Malignant hyperthermia in humans-Standardization of contracture testing protocol. Anesth Analg1989;69:437–443.
53.
LarachMG. Standardization of the caffeine halothane muscle contracture test. Anesth Analg1989;69(4):511–515.
54.
KalowW, BrittBA, ChenFY. Epidemiology and inheritance of malignant hyperthermia. In: BrittBA, ed. Malignant hyperthermia. Int Anesthesiol Clin1979;17:119–139.
55.
DonlonJV, NewfieldP, SreterF, RyanJF. Implications of masseter spasm after succinylcholine. Anesthesiology1987;49(4):298–301.
56.
SchwartzL, KokaBV, RockoffMA. Masseter spasm after halothane and succinylcholine: Incidence and implications (abstract). Anesthesiology1983;59(3):A438.
OhnishiST, KatagiH, OhnishiT, BrownellAKW. Detection of malignant hyperthermia susceptibility using a spin label technique on red blood cells. Br J Anaesth1988;61(5):565–568.
60.
OleinJ, ArzovZ, RosenbergH, TuchlerM, ChanceB.Non-invasive evaluation of malignant hyperthermia susceptibility with phosphorus nuclear magnetic resonance spectroscopy. Anesthesiology1988;68(4):507–513.
61.
KlipA, RamlalT, WalkerD, BrittBA, ElliotME. Selective increase in cytoplasmic calcium by anesthetic in lymphocytes from malignant hyperthermia-susceptible pigs. Anesth Analg1987;66(5):381–385.
62.
AmaranathL, LavinTJ, TrussoRA, BoutrosAR. Evaluation of creatine phosphokinase screening as a predictor of malignant hyperthermia. Br J Anaesth1983;55(6):531–533.
63.
BrittBA, EndrenyiL, KalowW, PetersPL. The adenosine triphosphate (ATP) depletion test: Comparison with the caffeine contracture test as a method of diagnosing malignant hyperthermia susceptibility. Can Anaesth Soc J1976;23:624–635.
64.
AllenPD, RyanJF, JonesDE, . Sarcoplasmic reticulum calcium uptake in cryostat sections of skeletal muscle from malignant hyperthermia patients and controls. Muscle & Nerve1986;9:474–475.
65.
HarrisonGG, VerburgC.Erythrocyte osmotic susceptibility in hyperthermia-susceptible swine. Br J Anaesth1973;45:131–133.
66.
TolpinEI, FletcherJE, RosenbergH, MichauxK.Effects of anesthetic agents in erythrocyte fragility: Comparison of normal and malignant hyperthermia susceptible patients. Can J Anaesth1987;34(4):366–372.
67.
ReynoldsAC, ReynoldsEV, HenschelEO. Physical exercise in malignant hyperthermia screening. Lancet1981;2:303.
68.
MacLennanDH, DuffC, ZorzatoF, . Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature1990;343:559–562.
69.
McCarthyTV, HealyJMS, HeffronJJA, . Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature1990;343:562–564.
70.
McPhersonFW, TaylorCAJr. The King syndrome: Malignant hyperthermia, myopathy and multiple anomalies. Am J Med Genet1981;8:154–165.
71.
KousseffBG, NicholsP.A new autosomal recessive syndrome with Noonan-like phenotype, myopathy with congenital contractures and malignant hyperthermia. Birth Defects1985;21(2):111–117.
72.
NelsonTE. SR function in malignant hyperthermia. Cell Calcium1988;9(5-6):257–265.
73.
BrittBA, KalowW, GordonA, HumphreyJG, NewcastleNB. Malignant hyperthermia: An investigation of five patients. Can Anaesth Soc J1973;20(4):431–467.
74.
AllenPD, RyanJF, SreterFA, MabuchiK.Rigid vs non-rigid malignant hyperthermia. Studies of Ca uptake and actinomyosin ATPase (abstract). Anesthesiology1980;53(3):S251.
75.
O'BrienPJ. Porcine malignant hyperthermia susceptibility: Hypersensitive calcium release mechanism of skeletal muscle sarcoplasmic reticulum. Can J Vet Res1986;50(3):318–328.
76.
LopezJR, AlamoL, CaputoC, WikinskiJ, LedezmaD.Intracellular ionized calcium concentration in muscles from humans with malignant hyperthermia. Muscle & Nerve1985;8:355–358.
77.
CondrescuM, LopezJR, MedinaP, AlamoL.Deficient function of the sarcoplasmic reticulum in patients susceptible to malignant hyperthermia. Muscle & Nerve1987;10(3):238–241.
78.
OhnishiST, WaringAJ, FangSRG, . Abnormal membrane properties of the sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia: Modes of action of halothane, caffeine, dantrolene and two other drugs. Arch Biochem Biophys1986;247(2):294–301.
79.
MouldsRFW, DenboroughMA. Biochemical basis of malignant hyperthermia. Br Med J1974;2:241–244.
80.
KlipA, BrittBA, ElliotME, WalkerD, RamlalT, PegeW.Changes in cytoplasmic-free calcium caused by halothane: Role of the plasma membrane cell intracellular Ca stores. Biochem Cell Biol1986;64(11):1181–1189.
81.
MickelsonJR, RossJA, HyslopRJ, GallantEM, LouisCF. Skeletal muscle sarcolemma in malignant hyperthermia: Evidence for a defect in calcium regulation. Biochim Biophys Acta1987;897(3):364–376.
82.
RockE, Kozak-ReissG.Effect of halothane on the Ca-transport system of surface membranes isolated from normal and malignant hyperthermia pig skeletal muscle. Arch Biochem Biophys1987;256(2):703–707.
83.
CheahKS, CheahAM. Skeletal muscle mitochondrial phospholipase A2 and the interaction of mitochondria and sarcoplasmic reticulum in porcine malignant hyperthermia. Biochim Biophys Acta1981;638(1):40–49.
84.
FletcherJE, RosenbergH, HilfM.Possible phospholipase A2 involvement in human malignant hyperthermia (abstract). Anesthesiology1984;61(3A):A252.
85.
FletcherJE, RosenbergH.In vitro muscle contractures induced by halothane and suxamethonium II: Human skeletal muscle from normal and malignant hyperthermia susceptible patients. Br J Anaesth1986;58(2):1433–1439.
86.
MessineoFC, RathierM, FavreauC, WatrasJ, TakenakaH.Mechanisms of fatty acid effects on sarcoplasmic reticulum. J Biol Chem1984;259(2):1336–1343.
87.
StadhoudersAM, VieringWAL, VerburgMP, RuitenbeekW, SengersRCA. In vivo induced malignant hyperthermia in pigs III: Localization of calcium in skeletal muscle mitochondria by means of electromicroscopy and micro-probe analysis. Acta Anaesthesiol Scand1984;28:14–26.
88.
VerburgMP, OerlemansFTJJ, Van BennekomCA, GielenMJM, DeBroynCHMM, CrulJF. In vivo induced malignant hyperthermia in pigs I: Physiological and biochemical changes and the influence of dantrolene sodium. Acta Anaesthesiol Scand1984;28:1–8.
89.
RuitenbeekW, VerburgMP, JanssenAJM, StadhoudersAM, SengersRCA. In vivo induced malignant hyperthermia in pigs II: Metabolism of skeletal muscle mitochondria. Acta Anaesthesiol Scand1984;28:9–13.
90.
MitchellG, HeffronJJA, Van RensburgAJJ. A halothane-induced biochemical defect in muscle of normal and malignant hyperthermia-susceptible landrace pigs. Anesth Analg1980;59:250–256.
91.
WilliamsRD, NicholsRJJr, DentTE, AllenCE. Disturbances of the oxidative-phosphorylation mechanism as a possible etiological factor in sudden unexplained hyperpyrexia occurring during anesthesia. Anesthesiology1966;27(2):231–232.
92.
WangJK, MoffittEA, RosevearJW. Oxidative phosphorylation in acute hyperthermia. Anesthesiology1969;30(4):439–442.
93.
FuchsF.Thermal inactivation of the calcium regulatory mechanism of human skeletal muscle actinomyosin: A possible contributing factor in the rigidity of malignant hyperthermia. Anesthesiology1975;42(5):584–589.
